NCT01404936View on ClinicalTrials.gov

Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 1996

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Lymphoma
Interventions
DRUG

Interferon-2A

4 (x106 IU/m\^2) subcutaneously on days 1-4.

DRUG

Adriamycin

25 mg/m\^2 by vein on day 4.

DRUG

Bleomycin

10 mg/m\^2 by vein on day 4.

DRUG

Velban

6 mg/m\^2 by vein on day 4.

DRUG

Dacarbazine

375 mg/m\^2 by vein on day 4.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Schering-Plough
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER